Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 410


Redox Regulation in the Base Excision Repair Pathway: Old and New Players as Cancer Therapeutic Targets.

Rajapakse A, Suraweera A, Boucher D, Naqi A, O'Byrne K, Richard DJ, Croft LV.

Curr Med Chem. 2019 Apr 29. doi: 10.2174/0929867326666190430092732. [Epub ahead of print]


Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer.

Park K, Bennouna J, Boyer M, Hida T, Hirsh V, Kato T, Lu S, Mok T, Nakagawa K, O'Byrne K, Paz-Ares L, Schuler M, Sibilot DM, Tan EH, Tanaka H, Wu YL, Yang JC, Zhang L, Zhou C, Märten A, Tang W, Yamamoto N.

Lung Cancer. 2019 Jun;132:126-131. doi: 10.1016/j.lungcan.2019.04.014. Epub 2019 Apr 10.


Nivolumab plus ipilimumab in non-small-cell lung cancer.

Reck M, Borghaei H, O'Byrne KJ.

Future Oncol. 2019 May 8. doi: 10.2217/fon-2019-0031. [Epub ahead of print]


Rearranged During Transfection Fusions in Non-Small Cell Lung Cancer.

O'Leary C, Xu W, Pavlakis N, Richard D, O'Byrne K.

Cancers (Basel). 2019 May 3;11(5). pii: E620. doi: 10.3390/cancers11050620. Review.


Isolation of circulating tumor cells in non-small-cell-lung-cancer patients using a multi-flow microfluidic channel.

Zhou J, Kulasinghe A, Bogseth A, O'Byrne K, Punyadeera C, Papautsky I.

Microsyst Nanoeng. 2019 Feb 25;5:8. doi: 10.1038/s41378-019-0045-6. eCollection 2019.


Splenic mass diagnosis in dogs undergoing splenectomy according to breed size.

O'Byrne K, Hosgood G.

Vet Rec. 2019 May 18;184(20):620. doi: 10.1136/vr.104983. Epub 2019 Apr 30.


Dasatinib Treatment Increases Sensitivity to c-Met Inhibition in Triple-Negative Breast Cancer Cells.

Gaule P, Mukherjee N, Corkery B, Eustace AJ, Gately K, Roche S, O'Connor R, O'Byrne KJ, Walsh N, Duffy MJ, Crown J, O'Donovan N.

Cancers (Basel). 2019 Apr 17;11(4). pii: E548. doi: 10.3390/cancers11040548.


Role of the posterodorsal medial amygdala in predator odour stress-induced puberty delay in female rats.

Li XF, Adekunbi DA, Alobaid HM, Li S, Pilot M, Lightman SL, O'Byrne KT.

J Neuroendocrinol. 2019 Jun;31(6):e12719. doi: 10.1111/jne.12719. Epub 2019 Apr 29.


Lipopolysaccharide reduces gonadotrophin-releasing hormone (GnRH) gene expression: role of RFamide-related peptide-3 and kisspeptin.

Lee CY, Li S, Li XF, Stalker DAE, Cooke C, Shao B, Kelestimur H, Henry BA, Conductier G, O'Byrne KT, Clarke IJ.

Reprod Fertil Dev. 2019 Mar 29. doi: 10.1071/RD18277. [Epub ahead of print]


Phenotypic Characterization of Circulating Lung Cancer Cells for Clinically Actionable Targets.

Kulasinghe A, Kapeleris J, Cooper C, Warkiani ME, O'Byrne K, Punyadeera C.

Cancers (Basel). 2019 Mar 18;11(3). pii: E380. doi: 10.3390/cancers11030380.


When RON MET TAM in Mesothelioma: All Druggable for One, and One Drug for All?

Baird AM, Easty D, Jarzabek M, Shiels L, Soltermann A, Klebe S, Raeppel S, MacDonagh L, Wu C, Griggs K, Kirschner MB, Stanfill B, Nonaka D, Goparaju CM, Murer B, Fennell DA, O'Donnell DM, Barr MP, Mutti L, Reid G, Finn S, Cuffe S, Pass HI, Opitz I, Byrne AT, O'Byrne KJ, Gray SG.

Front Endocrinol (Lausanne). 2019 Feb 26;10:89. doi: 10.3389/fendo.2019.00089. eCollection 2019.


First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers.

Ready N, Hellmann MD, Awad MM, Otterson GA, Gutierrez M, Gainor JF, Borghaei H, Jolivet J, Horn L, Mates M, Brahmer J, Rabinowitz I, Reddy PS, Chesney J, Orcutt J, Spigel DR, Reck M, O'Byrne KJ, Paz-Ares L, Hu W, Zerba K, Li X, Lestini B, Geese WJ, Szustakowski JD, Green G, Chang H, Ramalingam SS.

J Clin Oncol. 2019 Apr 20;37(12):992-1000. doi: 10.1200/JCO.18.01042. Epub 2019 Feb 20.


First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression.

Schuler M, Tan EH, O'Byrne K, Zhang L, Boyer M, Mok T, Hirsh V, Yang JC, Lee KH, Lu S, Shi Y, Kim SW, Laskin J, Kim DW, Arvis CD, Kölbeck K, Massey D, Märten A, Paz-Ares L, Park K.

J Cancer Res Clin Oncol. 2019 Jun;145(6):1569-1579. doi: 10.1007/s00432-019-02862-x. Epub 2019 Feb 19.


The prognostic significance of circulating tumor cells in head and neck and non-small-cell lung cancer.

Kulasinghe A, Kapeleris J, Kimberley R, Mattarollo SR, Thompson EW, Thiery JP, Kenny L, O'Byrne K, Punyadeera C.

Cancer Med. 2018 Dec;7(12):5910-5919. doi: 10.1002/cam4.1832. Epub 2018 Nov 22.


Maternal High Triglyceride Levels During Early Pregnancy and Risk of Preterm Delivery: A Retrospective Cohort Study.

Lin XH, Wu DD, Li C, Xu YJ, Gao L, Lass G, Zhang J, Tian S, Ivanova D, Tang L, Chen L, Ding R, Liu XM, Han M, Fan JX, Li XF, Sheng JZ, O'Byrne KT, Huang HF.

J Clin Endocrinol Metab. 2019 Apr 1;104(4):1249-1258. doi: 10.1210/jc.2018-01372.


The Prognostic Role of Circulating Tumor Cells (CTCs) in Lung Cancer.

Kapeleris J, Kulasinghe A, Warkiani ME, Vela I, Kenny L, O'Byrne K, Punyadeera C.

Front Oncol. 2018 Aug 14;8:311. doi: 10.3389/fonc.2018.00311. eCollection 2018. Review.


Tissue and Blood Biomarkers in Lung Cancer: A Review.

Duffy MJ, O'Byrne K.

Adv Clin Chem. 2018;86:1-21. doi: 10.1016/bs.acc.2018.05.001. Epub 2018 May 30. Review.


Pembrolizumab as Palliative Immunotherapy in Malignant Pleural Mesothelioma.

Metaxas Y, Rivalland G, Mauti LA, Klingbiel D, Kao S, Schmid S, Nowak AK, Gautschi O, Bartnick T, Hughes BG, Bouchaab H, Rothschild SI, Pavlakis N, Wolleb S, Petrausch U, O'Byrne K, Froesch P, Löffler-Baumann M, Pratsch-Peter S, Russell P, Mingrone W, Savic S, Thapa B, Früh M, Pless M, von Moos R, John T.

J Thorac Oncol. 2018 Nov;13(11):1784-1791. doi: 10.1016/j.jtho.2018.08.007. Epub 2018 Aug 22.


EV, Microvesicles/MicroRNAs and Stem Cells in Cancer.

Tickner JA, Richard DJ, O'Byrne KJ.

Adv Exp Med Biol. 2018;1056:123-135. doi: 10.1007/978-3-319-74470-4_8. Review.


Correction: Modulating lysosomal function through lysosome membrane permeabilization or autophagy suppression restores sensitivity to cisplatin in refractory non-small-cell lung cancer cells.

Circu M, Cardelli J, Barr MP, O'Byrne K, Mills G, El-Osta H.

PLoS One. 2018 May 2;13(5):e0197016. doi: 10.1371/journal.pone.0197016. eCollection 2018.


Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.

Hellmann MD, Ciuleanu TE, Pluzanski A, Lee JS, Otterson GA, Audigier-Valette C, Minenza E, Linardou H, Burgers S, Salman P, Borghaei H, Ramalingam SS, Brahmer J, Reck M, O'Byrne KJ, Geese WJ, Green G, Chang H, Szustakowski J, Bhagavatheeswaran P, Healey D, Fu Y, Nathan F, Paz-Ares L.

N Engl J Med. 2018 May 31;378(22):2093-2104. doi: 10.1056/NEJMoa1801946. Epub 2018 Apr 16.


Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials.

Wu YL, Sequist LV, Tan EH, Geater SL, Orlov S, Zhang L, Lee KH, Tsai CM, Kato T, Barrios CH, Schuler M, Hirsh V, Yamamoto N, O'Byrne K, Boyer M, Mok T, Peil B, Märten A, Chih-Hsin Yang J, Paz-Ares L, Park K.

Clin Lung Cancer. 2018 Jul;19(4):e465-e479. doi: 10.1016/j.cllc.2018.03.009. Epub 2018 Mar 17.


BBI608 inhibits cancer stemness and reverses cisplatin resistance in NSCLC.

MacDonagh L, Gray SG, Breen E, Cuffe S, Finn SP, O'Byrne KJ, Barr MP.

Cancer Lett. 2018 Aug 1;428:117-126. doi: 10.1016/j.canlet.2018.04.008. Epub 2018 Apr 11.


Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi.

Suraweera A, O'Byrne KJ, Richard DJ.

Front Oncol. 2018 Mar 29;8:92. doi: 10.3389/fonc.2018.00092. eCollection 2018. Review.


A Socio-Technical Exploration for Reducing & Mitigating the Risk of Retained Foreign Objects.

Corrigan S, Kay A, O'Byrne K, Slattery D, Sheehan S, McDonald N, Smyth D, Mealy K, Cromie S.

Int J Environ Res Public Health. 2018 Apr 10;15(4). pii: E714. doi: 10.3390/ijerph15040714.


Development and characterisation of a panel of phosphatidylinositide 3-kinase - mammalian target of rapamycin inhibitor resistant lung cancer cell lines.

Heavey S, Dowling P, Moore G, Barr MP, Kelly N, Maher SG, Cuffe S, Finn SP, O'Byrne KJ, Gately K.

Sci Rep. 2018 Jan 26;8(1):1652. doi: 10.1038/s41598-018-19688-1.


Kisspeptin neurones in the posterodorsal medial amygdala modulate sexual partner preference and anxiety in male mice.

Adekunbi DA, Li XF, Lass G, Shetty K, Adegoke OA, Yeo SH, Colledge WH, Lightman SL, O'Byrne KT.

J Neuroendocrinol. 2018 Mar;30(3):e12572. doi: 10.1111/jne.12572.


Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6).

Wu YL, Hirsh V, Sequist LV, Hu CP, Feng J, Lu S, Huang Y, Schuler M, Mok T, Yamamoto N, O'Byrne K, Geater SL, Zhou C, Massey D, Märten A, Lungershausen J, Yang JC.

Patient. 2018 Feb;11(1):131-141. doi: 10.1007/s40271-017-0287-z.


Targeting the cancer stem cell marker, aldehyde dehydrogenase 1, to circumvent cisplatin resistance in NSCLC.

MacDonagh L, Gallagher MF, Ffrench B, Gasch C, Breen E, Gray SG, Nicholson S, Leonard N, Ryan R, Young V, O'Leary JJ, Cuffe S, Finn SP, O'Byrne KJ, Barr MP.

Oncotarget. 2017 Aug 3;8(42):72544-72563. doi: 10.18632/oncotarget.19881. eCollection 2017 Sep 22.


Modulating lysosomal function through lysosome membrane permeabilization or autophagy suppression restores sensitivity to cisplatin in refractory non-small-cell lung cancer cells.

Circu M, Cardelli J, Barr MP, O'Byrne K, Mills G, El-Osta H.

PLoS One. 2017 Sep 25;12(9):e0184922. doi: 10.1371/journal.pone.0184922. eCollection 2017. Erratum in: PLoS One. 2018 May 2;13(5):e0197016.


Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer.

Govindan R, Szczesna A, Ahn MJ, Schneider CP, Gonzalez Mella PF, Barlesi F, Han B, Ganea DE, Von Pawel J, Vladimirov V, Fadeeva N, Lee KH, Kurata T, Zhang L, Tamura T, Postmus PE, Jassem J, O'Byrne K, Kopit J, Li M, Tschaika M, Reck M.

J Clin Oncol. 2017 Oct 20;35(30):3449-3457. doi: 10.1200/JCO.2016.71.7629. Epub 2017 Aug 30.


Role of amygdala kisspeptin in pubertal timing in female rats.

Adekunbi DA, Li XF, Li S, Adegoke OA, Iranloye BO, Morakinyo AO, Lightman SL, Taylor PD, Poston L, O'Byrne KT.

PLoS One. 2017 Aug 28;12(8):e0183596. doi: 10.1371/journal.pone.0183596. eCollection 2017.


Pembrolizumab-Induced Encephalopathy: A Review of Neurological Toxicities with Immune Checkpoint Inhibitors.

Feng S, Coward J, McCaffrey E, Coucher J, Kalokerinos P, O'Byrne K.

J Thorac Oncol. 2017 Nov;12(11):1626-1635. doi: 10.1016/j.jtho.2017.08.007. Epub 2017 Aug 24. Review.


Hypothalamic effects of progesterone on regulation of the pulsatile and surge release of luteinising hormone in female rats.

He W, Li X, Adekunbi D, Liu Y, Long H, Wang L, Lyu Q, Kuang Y, O'Byrne KT.

Sci Rep. 2017 Aug 14;7(1):8096. doi: 10.1038/s41598-017-08805-1.


Carboplatin versus two doses of cisplatin in combination with gemcitabine in the treatment of advanced non-small-cell lung cancer: Results from a British Thoracic Oncology Group randomised phase III trial.

Ferry D, Billingham L, Jarrett H, Dunlop D, Woll PJ, Nicolson M, Shah R, Thompson J, Spicer J, Muthukumar D, Skailes G, Leonard P, Chetiyawardana AD, Wells P, Lewanski C, Crosse B, Hill M, Gaunt P, O'Byrne K.

Eur J Cancer. 2017 Sep;83:302-312. doi: 10.1016/j.ejca.2017.05.037. Epub 2017 Aug 4.


Tyrosine kinase inhibitors as modulators of trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity in breast cancer cell lines.

Collins DM, Gately K, Hughes C, Edwards C, Davies A, Madden SF, O'Byrne KJ, O'Donovan N, Crown J.

Cell Immunol. 2017 Sep;319:35-42. doi: 10.1016/j.cellimm.2017.07.005. Epub 2017 Jul 15.


Immune checkpoint inhibitors: Navigating a new paradigm of treatment toxicities.

Roberts K, Culleton V, Lwin Z, O'Byrne K, Hughes BG.

Asia Pac J Clin Oncol. 2017 Aug;13(4):277-288. doi: 10.1111/ajco.12698. Epub 2017 Jul 12. Review.


hSSB1 associates with and promotes stability of the BLM helicase.

Croft LV, Ashton NW, Paquet N, Bolderson E, O'Byrne KJ, Richard DJ.

BMC Mol Biol. 2017 May 15;18(1):13. doi: 10.1186/s12867-017-0090-3.


Nucleolar caspase-2: Protecting us from DNA damage.

O'Byrne KJ, Richard DJ.

J Cell Biol. 2017 Jun 5;216(6):1521-1523. doi: 10.1083/jcb.201704114. Epub 2017 May 12.


Expression of CDCA3 Is a Prognostic Biomarker and Potential Therapeutic Target in Non-Small Cell Lung Cancer.

Adams MN, Burgess JT, He Y, Gately K, Snell C, Zhang SD, Hooper JD, Richard DJ, O'Byrne KJ.

J Thorac Oncol. 2017 Jul;12(7):1071-1084. doi: 10.1016/j.jtho.2017.04.018. Epub 2017 May 6.


hSSB1 phosphorylation is dynamically regulated by DNA-PK and PPP-family protein phosphatases.

Ashton NW, Paquet N, Shirran SL, Bolderson E, Kariawasam R, Touma C, Fallahbaghery A, Gamsjaeger R, Cubeddu L, Botting C, Pollock PM, O'Byrne KJ, Richard DJ.

DNA Repair (Amst). 2017 Jun;54:30-39. doi: 10.1016/j.dnarep.2017.03.006. Epub 2017 Apr 6.


Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial.

Paz-Ares L, Tan EH, O'Byrne K, Zhang L, Hirsh V, Boyer M, Yang JC, Mok T, Lee KH, Lu S, Shi Y, Lee DH, Laskin J, Kim DW, Laurie SA, Kölbeck K, Fan J, Dodd N, Märten A, Park K.

Ann Oncol. 2017 Feb 1;28(2):270-277. doi: 10.1093/annonc/mdw611.


A Rare Case of Omentum Invasive Prostate Cancer: Staging With PSMA PET/CT Imaging and Response to Systemic Therapy.

Ladwa R, Gustafson S, McCaffrey E, Miles K, O'Byrne K.

Clin Nucl Med. 2017 Jun;42(6):e311-e312. doi: 10.1097/RLU.0000000000001619.


Enrichment of circulating head and neck tumour cells using spiral microfluidic technology.

Kulasinghe A, Tran TH, Blick T, O'Byrne K, Thompson EW, Warkiani ME, Nelson C, Kenny L, Punyadeera C.

Sci Rep. 2017 Feb 15;7:42517. doi: 10.1038/srep42517.


Kdm6a and Kdm6b: Altered expression in malignant pleural mesothelioma.

Cregan S, Breslin M, Roche G, Wennstedt S, MacDonagh L, Albadri C, Gao Y, O'Byrne KJ, Cuffe S, Finn SP, Gray SG.

Int J Oncol. 2017 Mar;50(3):1044-1052. doi: 10.3892/ijo.2017.3870. Epub 2017 Feb 9.


EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6.

Wu YL, Sequist LV, Hu CP, Feng J, Lu S, Huang Y, Li W, Hou M, Schuler M, Mok T, Yamamoto N, O'Byrne K, Hirsh V, Gibson N, Massey D, Kim M, Yang JC.

Br J Cancer. 2017 Jan 17;116(2):175-185. doi: 10.1038/bjc.2016.420. Epub 2016 Dec 22.


Novel insight into the composition of human single-stranded DNA-binding protein 1 (hSSB1)-containing protein complexes.

Ashton NW, Loo D, Paquet N, O'Byrne KJ, Richard DJ.

BMC Mol Biol. 2016 Dec 9;17(1):24.


Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung.

Spigel DR, Edelman MJ, O'Byrne K, Paz-Ares L, Mocci S, Phan S, Shames DS, Smith D, Yu W, Paton VE, Mok T.

J Clin Oncol. 2017 Feb;35(4):412-420. doi: 10.1200/JCO.2016.69.2160. Epub 2016 Dec 12.


Activation and cleavage of SASH1 by caspase-3 mediates an apoptotic response.

Burgess JT, Bolderson E, Adams MN, Baird AM, Zhang SD, Gately KA, Umezawa K, O'Byrne KJ, Richard DJ.

Cell Death Dis. 2016 Nov 10;7(11):e2469. doi: 10.1038/cddis.2016.364.


Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials.

Yang JC, Sequist LV, Zhou C, Schuler M, Geater SL, Mok T, Hu CP, Yamamoto N, Feng J, O'Byrne K, Lu S, Hirsh V, Huang Y, Sebastian M, Okamoto I, Dickgreber N, Shah R, Märten A, Massey D, Wind S, Wu YL.

Ann Oncol. 2016 Nov;27(11):2103-2110. Epub 2016 Sep 6.


Supplemental Content

Loading ...
Support Center